Results 71 to 80 of about 26,190 (208)
Natural Products as Modulators of ABC Transporters in Breast Cancer
ABSTRACT Breast cancer remains a significant global health challenge, with high incidence and mortality rates despite advancements in early detection and treatment. Multidrug resistance (MDR), particularly in aggressive subtypes like triple‐negative breast cancer (TNBC), continues to hinder effective therapy.
Yoganishalini Sagadevan +2 more
wiley +1 more source
Future Perspective of Chemotherapy and Pharmacotherapy in Thymic Carcinoma
Thymic carcinoma is a rare cancer that arises from thymic epithelial cells. Its nature and pathology differ from that of benign thymoma, presenting a poorer prognosis.
Yusuke Okuma, Rui Kitadai
core +1 more source
Schematic overview of progression from differentiated thyroid carcinoma (DTC) to anaplastic thyroid carcinoma (ATC). ATC primarily develops via two pathways: the BRAF p.V600E‐mutated papillary thyroid carcinoma (PTC) pathway and the RAS‐mutated pathway. The origin and progression of BRAF/RAS‐wildtype ATC remain unclear.
Toru Odate, Tetsuo Kondo
wiley +1 more source
Relationship of possible biomarkers with malignancy of thymic tumors: a meta-analysis
Background Role of biomarkers for promotion of tumor proliferation (BPTPs) and for promotion of apoptosis (BPAs) in thymic malignant tumors is still unclear.
Huilan Zeng +7 more
doaj +1 more source
A spontaneous reduction in tumor size of a thymic carcinoma: a case report
Background Spontaneous regression of thymic carcinoma is extremely rare. We report a case of a resected thymic carcinoma with preoperative spontaneous regression in a 67-year-old woman.
Shoei Kuroki +4 more
doaj +1 more source
MTAP Deficiency as a Metabolic Vulnerability in Cancer: Implications for Synthetic Lethal Therapy
MTAP deletion creates a therapeutically actionable metabolic vulnerability through MTA accumulation and PRMT5 dependency. This review summarizes the biochemical basis of MTAP‐directed synthetic lethality, emerging PRMT5/MAT2A inhibitors, clinicogenomic features of MTAP‐deleted tumors, and future strategies for precision oncology.
Hiroaki Ikushima, Hidenori Kage
wiley +1 more source
Trophoblast Cell Surface Antigen 2 Expression in Thymic Carcinoma: Brief Report
Introduction: Trophoblast cell surface antigen 2 (TROP2) is a transmembrane glycoprotein overexpressed in various cancer types. Although TROP2-targeting therapy is currently attracting attention, little is known about TROP2 expression in thymic carcinoma.
Kana Kurokawa, MD, PhD +17 more
doaj +1 more source
THYMIC CARCINOMA - A RARE CASE REPORT
Introduction. Thymic carcinoma is a rare, invasive mediastinal neoplasm with a tendency to metastasize. They constitute a heterogeneous group of tumors that present differently in terms of both behavior and prognosis. Case report.
Arnav Kr Roychoudhury +2 more
core +1 more source
Malignancy in Pediatric Hyperfunctioning Thyroid Nodules: A Case Report and Literature Review
ABSTRACT Background Thyroid nodules are rare in children but carry a markedly higher risk of malignancy compared to adults (20%–26% vs. 5%). Hyperfunctioning thyroid nodules are exceptionally uncommon in the pediatric population and are typically benign.
Cristina Clausi +12 more
wiley +1 more source
Salvage surgery for stage IVa thymic carcinoma combined with aortic arch resection – case report
Background Although complete surgical resection of thymic carcinoma is a prognostic factor, extended surgery combined with a major blood vessel procedure remains controversial because of the increased risk of mortality.
Hiroyuki Yamato +6 more
doaj +1 more source

